Health care stocks were edging higher premarket Tuesday with the iShares Biotechnology ETF (IBB) advancing by 0.8% and the Health Care Select Sector SPDR Fund (XLV) recently up 0.6%.
Nektar Therapeutics (NKTR) shares were surging by more than 110% after the company said the phase 2b study of investigational rezpegaldesleukin met its primary endpoint in patients with moderate to severe atopic dermatitis.
Amarin (AMRN) shares were up nearly 9% after the company said it signed an exclusive license and supply agreement with Recordati to commercialize Vazkepa in 59 European countries.
Nuvation Bio (NUVB) shares were more than 2% higher after the compay said taletrectinib has been added as a preferred agent in the updated National Comprehensive Cancer Network clinical practice guidelines for non-small cell lung cancer, or NSCLC.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。